Plain-English translation of NCT05266898 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing how well Gardasil-9, an HPV vaccine, works in people living with HIV who have their virus under control. HPV (human papillomavirus) can increase the risk of certain cancers, especially in people with HIV. The study will measure whether your body builds protective immunity after receiving the vaccine series.
People living with HIV face higher risks from HPV-related cancers, but we don't have enough information about how well this newer vaccine works in this population. This trial will help doctors understand if the vaccine is effective and safe for you.
You likely qualify if…
You likely don't qualify if…
If you're in the vaccine group, you'll receive three doses of Gardasil-9 over a period of time, with blood tests to check how well your body responds to the vaccine. If you're in the comparison group, researchers will review your previous vaccine records and draw blood to measure your antibody levels. Either way, you'll have clinic visits for vaccinations and/or blood draws, and the research team will monitor how your body's immune system responds.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States